Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.
Identifieur interne : 002D00 ( PubMed/Corpus ); précédent : 002C99; suivant : 002D01Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.
Auteurs : Alexander Bukreyev ; Elaine W. Lamirande ; Ursula J. Buchholz ; Leatrice N. Vogel ; William R. Elkins ; Marisa St Claire ; Brian R. Murphy ; Kanta Subbarao ; Peter L. CollinsSource :
- Lancet (London, England) [ 1474-547X ] ; 2004.
English descriptors
- KwdEn :
- Administration, Intranasal, Animals, Antibodies, Viral (blood), Chlorocebus aethiops, DNA, Recombinant, Immunity, Mucosal, Membrane Glycoproteins (immunology), Membrane Glycoproteins (metabolism), Nasal Mucosa (virology), Parainfluenza Vaccines, Parainfluenza Virus 3, Bovine (immunology), Parainfluenza Virus 3, Bovine (isolation & purification), Parainfluenza Virus 3, Bovine (metabolism), Respiratory Mucosa (immunology), SARS Virus (immunology), SARS Virus (isolation & purification), SARS Virus (metabolism), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (prevention & control), Spike Glycoprotein, Coronavirus, Therapeutic Irrigation, Trachea, Vaccination, Vaccines, Attenuated, Viral Envelope Proteins (immunology), Viral Envelope Proteins (metabolism), Viral Vaccines (administration & dosage), Viral Vaccines (immunology).
- MESH :
- chemical , administration & dosage : Viral Vaccines.
- chemical , blood : Antibodies, Viral.
- chemical , immunology : Membrane Glycoproteins, Viral Envelope Proteins, Viral Vaccines.
- chemical , metabolism : Membrane Glycoproteins, Viral Envelope Proteins.
- immunology : Parainfluenza Virus 3, Bovine, Respiratory Mucosa, SARS Virus, Severe Acute Respiratory Syndrome.
- isolation & purification : Parainfluenza Virus 3, Bovine, SARS Virus.
- metabolism : Parainfluenza Virus 3, Bovine, SARS Virus.
- prevention & control : Severe Acute Respiratory Syndrome.
- virology : Nasal Mucosa.
- Administration, Intranasal, Animals, Chlorocebus aethiops, DNA, Recombinant, Immunity, Mucosal, Parainfluenza Vaccines, Spike Glycoprotein, Coronavirus, Therapeutic Irrigation, Trachea, Vaccination, Vaccines, Attenuated.
Abstract
The outbreak of severe acute respiratory syndrome (SARS) in 2002 was caused by a previously unknown coronavirus-SARS coronavirus (SARS-CoV). We have developed an experimental SARS vaccine for direct immunisation of the respiratory tract, the major site of SARS- coronavirus transmission and disease.
DOI: 10.1016/S0140-6736(04)16501-X
PubMed: 15220033
Links to Exploration step
pubmed:15220033Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.</title><author><name sortKey="Bukreyev, Alexander" sort="Bukreyev, Alexander" uniqKey="Bukreyev A" first="Alexander" last="Bukreyev">Alexander Bukreyev</name><affiliation><nlm:affiliation>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. AB176v@nih.gov</nlm:affiliation></affiliation></author><author><name sortKey="Lamirande, Elaine W" sort="Lamirande, Elaine W" uniqKey="Lamirande E" first="Elaine W" last="Lamirande">Elaine W. Lamirande</name></author><author><name sortKey="Buchholz, Ursula J" sort="Buchholz, Ursula J" uniqKey="Buchholz U" first="Ursula J" last="Buchholz">Ursula J. Buchholz</name></author><author><name sortKey="Vogel, Leatrice N" sort="Vogel, Leatrice N" uniqKey="Vogel L" first="Leatrice N" last="Vogel">Leatrice N. Vogel</name></author><author><name sortKey="Elkins, William R" sort="Elkins, William R" uniqKey="Elkins W" first="William R" last="Elkins">William R. Elkins</name></author><author><name sortKey="St Claire, Marisa" sort="St Claire, Marisa" uniqKey="St Claire M" first="Marisa" last="St Claire">Marisa St Claire</name></author><author><name sortKey="Murphy, Brian R" sort="Murphy, Brian R" uniqKey="Murphy B" first="Brian R" last="Murphy">Brian R. Murphy</name></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name></author><author><name sortKey="Collins, Peter L" sort="Collins, Peter L" uniqKey="Collins P" first="Peter L" last="Collins">Peter L. Collins</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15220033</idno><idno type="pmid">15220033</idno><idno type="doi">10.1016/S0140-6736(04)16501-X</idno><idno type="wicri:Area/PubMed/Corpus">002D00</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002D00</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.</title><author><name sortKey="Bukreyev, Alexander" sort="Bukreyev, Alexander" uniqKey="Bukreyev A" first="Alexander" last="Bukreyev">Alexander Bukreyev</name><affiliation><nlm:affiliation>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. AB176v@nih.gov</nlm:affiliation></affiliation></author><author><name sortKey="Lamirande, Elaine W" sort="Lamirande, Elaine W" uniqKey="Lamirande E" first="Elaine W" last="Lamirande">Elaine W. Lamirande</name></author><author><name sortKey="Buchholz, Ursula J" sort="Buchholz, Ursula J" uniqKey="Buchholz U" first="Ursula J" last="Buchholz">Ursula J. Buchholz</name></author><author><name sortKey="Vogel, Leatrice N" sort="Vogel, Leatrice N" uniqKey="Vogel L" first="Leatrice N" last="Vogel">Leatrice N. Vogel</name></author><author><name sortKey="Elkins, William R" sort="Elkins, William R" uniqKey="Elkins W" first="William R" last="Elkins">William R. Elkins</name></author><author><name sortKey="St Claire, Marisa" sort="St Claire, Marisa" uniqKey="St Claire M" first="Marisa" last="St Claire">Marisa St Claire</name></author><author><name sortKey="Murphy, Brian R" sort="Murphy, Brian R" uniqKey="Murphy B" first="Brian R" last="Murphy">Brian R. Murphy</name></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name></author><author><name sortKey="Collins, Peter L" sort="Collins, Peter L" uniqKey="Collins P" first="Peter L" last="Collins">Peter L. Collins</name></author></analytic><series><title level="j">Lancet (London, England)</title><idno type="eISSN">1474-547X</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Intranasal</term><term>Animals</term><term>Antibodies, Viral (blood)</term><term>Chlorocebus aethiops</term><term>DNA, Recombinant</term><term>Immunity, Mucosal</term><term>Membrane Glycoproteins (immunology)</term><term>Membrane Glycoproteins (metabolism)</term><term>Nasal Mucosa (virology)</term><term>Parainfluenza Vaccines</term><term>Parainfluenza Virus 3, Bovine (immunology)</term><term>Parainfluenza Virus 3, Bovine (isolation & purification)</term><term>Parainfluenza Virus 3, Bovine (metabolism)</term><term>Respiratory Mucosa (immunology)</term><term>SARS Virus (immunology)</term><term>SARS Virus (isolation & purification)</term><term>SARS Virus (metabolism)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Spike Glycoprotein, Coronavirus</term><term>Therapeutic Irrigation</term><term>Trachea</term><term>Vaccination</term><term>Vaccines, Attenuated</term><term>Viral Envelope Proteins (immunology)</term><term>Viral Envelope Proteins (metabolism)</term><term>Viral Vaccines (administration & dosage)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Membrane Glycoproteins</term><term>Viral Envelope Proteins</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Membrane Glycoproteins</term><term>Viral Envelope Proteins</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Parainfluenza Virus 3, Bovine</term><term>Respiratory Mucosa</term><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Parainfluenza Virus 3, Bovine</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Parainfluenza Virus 3, Bovine</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Nasal Mucosa</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Intranasal</term><term>Animals</term><term>Chlorocebus aethiops</term><term>DNA, Recombinant</term><term>Immunity, Mucosal</term><term>Parainfluenza Vaccines</term><term>Spike Glycoprotein, Coronavirus</term><term>Therapeutic Irrigation</term><term>Trachea</term><term>Vaccination</term><term>Vaccines, Attenuated</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The outbreak of severe acute respiratory syndrome (SARS) in 2002 was caused by a previously unknown coronavirus-SARS coronavirus (SARS-CoV). We have developed an experimental SARS vaccine for direct immunisation of the respiratory tract, the major site of SARS- coronavirus transmission and disease.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15220033</PMID><DateCompleted><Year>2004</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>363</Volume><Issue>9427</Issue><PubDate><Year>2004</Year><Month>Jun</Month><Day>26</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.</ArticleTitle><Pagination><MedlinePgn>2122-7</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The outbreak of severe acute respiratory syndrome (SARS) in 2002 was caused by a previously unknown coronavirus-SARS coronavirus (SARS-CoV). We have developed an experimental SARS vaccine for direct immunisation of the respiratory tract, the major site of SARS- coronavirus transmission and disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We expressed the complete SARS coronavirus envelope spike (S) protein from a recombinant attenuated parainfluenza virus (BHPIV3) that is being developed as a live attenuated, intranasal paediatric vaccine against human parainfluenza virus type 3 (HPIV3). We immunised eight African green monkeys, four with a single dose of BHPIV3/ SARS-S and four with a control, BHPIV3/Ctrl, administered via the respiratory tract. A SARS-coronavirus challenge was given to all monkeys 28 days after immunisation.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Immunisation of animals with BHPIV3/SARS-S induced the production of SARS-coronavirus-neutralising serum antibodies, indicating that a systemic immune response resulted from mucosal immunisation. After challenge with SARS coronavirus, all monkeys in the control group shed SARS coronavirus, with shedding lasting 5-8 days. No viral shedding occurred in the group immunised with BHPIV3/SARS-S.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">A vectored mucosal vaccine expressing the SARS-coronavirus S protein alone may be highly effective in a single-dose format for the prevention of SARS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bukreyev</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. AB176v@nih.gov</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamirande</LastName><ForeName>Elaine W</ForeName><Initials>EW</Initials></Author><Author ValidYN="Y"><LastName>Buchholz</LastName><ForeName>Ursula J</ForeName><Initials>UJ</Initials></Author><Author ValidYN="Y"><LastName>Vogel</LastName><ForeName>Leatrice N</ForeName><Initials>LN</Initials></Author><Author ValidYN="Y"><LastName>Elkins</LastName><ForeName>William R</ForeName><Initials>WR</Initials></Author><Author ValidYN="Y"><LastName>St Claire</LastName><ForeName>Marisa</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>Brian R</ForeName><Initials>BR</Initials></Author><Author ValidYN="Y"><LastName>Subbarao</LastName><ForeName>Kanta</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Collins</LastName><ForeName>Peter L</ForeName><Initials>PL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004274">DNA, Recombinant</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578553">MHV surface projection glycoprotein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022241">Parainfluenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578557">spike glycoprotein, SARS-CoV</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2004 Jun 26;363(9427):2102-3</RefSource><PMID Version="1">15220029</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000281" MajorTopicYN="N">Administration, Intranasal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004274" MajorTopicYN="N">DNA, Recombinant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018928" MajorTopicYN="N">Immunity, Mucosal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009297" MajorTopicYN="N">Nasal Mucosa</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022241" MajorTopicYN="N">Parainfluenza Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029101" MajorTopicYN="N">Parainfluenza Virus 3, Bovine</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020545" MajorTopicYN="N">Respiratory Mucosa</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007507" MajorTopicYN="N">Therapeutic Irrigation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014132" MajorTopicYN="N">Trachea</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>6</Month><Day>29</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>7</Month><Day>14</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>6</Month><Day>29</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15220033</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(04)16501-X</ArticleId><ArticleId IdType="pii">S014067360416501X</ArticleId><ArticleId IdType="pmc">PMC7112367</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lancet. 2003 Jul 26;362(9380):263-70</Citation><ArticleIdList><ArticleId IdType="pubmed">12892955</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Comp Immunol Microbiol Infect Dis. 1981;4(2):175-89</Citation><ArticleIdList><ArticleId IdType="pubmed">6754243</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 1993 Nov;11(14):1395-404</Citation><ArticleIdList><ArticleId IdType="pubmed">8310760</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1998 Apr;72(4):2955-61</Citation><ArticleIdList><ArticleId IdType="pubmed">9525616</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Pediatr Infect Dis J. 1996 Aug;15(8):650-4</Citation><ArticleIdList><ArticleId IdType="pubmed">8858666</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Arch Virol. 1994;137(1-2):55-67</Citation><ArticleIdList><ArticleId IdType="pubmed">7979998</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Clin Invest. 2002 Jul;110(1):21-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12093883</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1998 Feb;72(2):891-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9444980</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2000 Aug;74(15):6821-31</Citation><ArticleIdList><ArticleId IdType="pubmed">10888621</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Exp Biol Med (Maywood). 2003 Jul;228(7):866-73</Citation><ArticleIdList><ArticleId IdType="pubmed">12876307</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 1995 Dec;172(6):1445-50</Citation><ArticleIdList><ArticleId IdType="pubmed">7594701</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 May 24;361(9371):1767-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12781535</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1995-2005</Citation><ArticleIdList><ArticleId IdType="pubmed">12671061</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 1990 Jan;174(1):87-94</Citation><ArticleIdList><ArticleId IdType="pubmed">2152996</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Apr;78(7):3572-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15016880</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2000 Jul;74(14):6448-58</Citation><ArticleIdList><ArticleId IdType="pubmed">10864657</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2003 Oct;77(20):10819-28</Citation><ArticleIdList><ArticleId IdType="pubmed">14512532</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2003 May 15;423(6937):240</Citation><ArticleIdList><ArticleId IdType="pubmed">12748632</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2001 May;75(10):4594-603</Citation><ArticleIdList><ArticleId IdType="pubmed">11312329</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2003 Oct 30;425(6961):915</Citation><ArticleIdList><ArticleId IdType="pubmed">14586458</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 Dec 18;349(25):2431-41</Citation><ArticleIdList><ArticleId IdType="pubmed">14681510</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Adv Exp Med Biol. 1995;380:265-70</Citation><ArticleIdList><ArticleId IdType="pubmed">8830490</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Clin Microbiol. 1991 Jun;29(6):1175-82</Citation><ArticleIdList><ArticleId IdType="pubmed">1650789</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2000 Oct;74(19):8922-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10982335</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D00 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002D00 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:15220033
|texte= Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:15220033" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |